Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 3/20 | 0.56 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397962 | 0.91 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL28475572 | 0.91 | ERBB2 (0.70) | ERBB2MINK1 | |
| SCHEMBL26316562 | 0.89 | ERBB2 (0.57) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL26316569 | 0.89 | ERBB2 (0.56) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL26316711 | 0.83 | ERBB2 (0.53) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL26316576 | 0.83 | ERBB2 (0.51) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL26316715 | 0.83 | ERBB2 (0.49) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL26316840 | 0.83 | ERBB2 (0.54) | ERBB2MINK1CYP19A1TYRADRB2 | |
| SCHEMBL3668068 | 0.82 | ERBB2 (0.80) | ERBB2MINK1CYP19A1TYR | |
| SCHEMBL3668064 | 0.82 | ERBB2 (0.80) | ERBB2MINK1CYP19A1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | ERBB2 2558/4885MINK1 1781/4885CYP19A1 1319/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | ERBB2 2443/4885MINK1 1986/4885CYP19A1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.